AbbVie ABBV generates a substantial portion of its revenues from its immunology franchise, driven by the encouraging uptake of its two blockbuster drugs — Skyrizi and Rinvoq. The robust demand for ...
Throughout 2025, AbbVie’s Skyrizi and Johnson & Johnson’s Tremfya were mainstays at the top of the monthly TV drug ad spending rankings. Indeed, since September, they’d taken turns alternating between ...
OpenAI’s secret hardware project with Apple design legend Jony Ive could be an AI-powered pen that’s basically ChatGPT in your hand, according to a newly surfaced patent. The smart pen packs a camera ...
AbbVie earns a buy rating, with strong 2025 EPS growth driven by Skyrizi and Rinvoq, despite pipeline concerns and a higher P/E. ABBV’s valuation remains attractive; a 14.4x FY 2027 multiple is ...
Psoriatic arthritis is an autoimmune condition that causes joint inflammation, skin symptoms, and pain. People searching for psoriatic arthritis prescriptions are often looking for detailed ...
AbbVie's major drugs, Skyrizi and Rinvoq, are generating lots of sales. Realty Income's diversified portfolio provides plenty of protection and monthly income. The JEPQ ETF employs a covered-call ...
Explore this year's advancements in gastroenterology biosimilars, highlighting key FDA approvals and market dynamics impacting IBD treatment options. The gastroenterology biosimilar landscape is ...
Hosted on MSN
Is AbbVie a buy, sell, or hold in 2026?
AbbVie's guidance for the next few years implies robust revenue growth. Some of the company's products are performing even better than expected. AbbVie's valuation and dividend program seal the deal.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback